BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

532 related articles for article (PubMed ID: 22766277)

  • 1. Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes.
    Holm K; Grabau D; Lövgren K; Aradottir S; Gruvberger-Saal S; Howlin J; Saal LH; Ethier SP; Bendahl PO; Stål O; Malmström P; Fernö M; Rydén L; Hegardt C; Borg Å; Ringnér M
    Mol Oncol; 2012 Oct; 6(5):494-506. PubMed ID: 22766277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The methyltransferase EZH2 is not required for mammary cancer development, although high EZH2 and low H3K27me3 correlate with poor prognosis of ER-positive breast cancers.
    Bae WK; Yoo KH; Lee JS; Kim Y; Chung IJ; Park MH; Yoon JH; Furth PA; Hennighausen L
    Mol Carcinog; 2015 Oct; 54(10):1172-80. PubMed ID: 25043748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features.
    Guo S; Li X; Rohr J; Wang Y; Ma S; Chen P; Wang Z
    Diagn Pathol; 2016 Apr; 11():41. PubMed ID: 27113214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poorly differentiated synovial sarcoma is associated with high expression of enhancer of zeste homologue 2 (EZH2).
    Changchien YC; Tátrai P; Papp G; Sápi J; Fónyad L; Szendrői M; Pápai Z; Sápi Z
    J Transl Med; 2012 Oct; 10():216. PubMed ID: 23110793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of histone 3 lysine 27 trimethylation (H3K27me3) and enhancer of Zest 2 (EZH2) in pediatric glial and glioneuronal tumors shows decreased H3K27me3 in H3F3A K27M mutant glioblastomas.
    Venneti S; Garimella MT; Sullivan LM; Martinez D; Huse JT; Heguy A; Santi M; Thompson CB; Judkins AR
    Brain Pathol; 2013 Sep; 23(5):558-64. PubMed ID: 23414300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of a constitutively active prolactin receptor causes histone trimethylation of the p53 gene in breast cancer.
    Tan D; Tang P; Huang J; Zhang J; Zhou W; Walker AM
    Chin Med J (Engl); 2014; 127(6):1077-83. PubMed ID: 24622438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flow-dependent epigenetic regulation of IGFBP5 expression by H3K27me3 contributes to endothelial anti-inflammatory effects.
    Xu S; Xu Y; Yin M; Zhang S; Liu P; Koroleva M; Si S; Little PJ; Pelisek J; Jin ZG
    Theranostics; 2018; 8(11):3007-3021. PubMed ID: 29896299
    [No Abstract]   [Full Text] [Related]  

  • 8. Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor-κB in hepatocellular carcinoma.
    Tsang DP; Wu WK; Kang W; Lee YY; Wu F; Yu Z; Xiong L; Chan AW; Tong JH; Yang W; Li MS; Lau SS; Li X; Lee SD; Yang Y; Lai PB; Yu DY; Xu G; Lo KW; Chan MT; Wang H; Lee TL; Yu J; Wong N; Yip KY; To KF; Cheng AS
    J Pathol; 2016 Apr; 238(5):651-64. PubMed ID: 26800240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of polycomb targets predicts breast cancer prognosis.
    Jene-Sanz A; Váraljai R; Vilkova AV; Khramtsova GF; Khramtsov AI; Olopade OI; Lopez-Bigas N; Benevolenskaya EV
    Mol Cell Biol; 2013 Oct; 33(19):3951-61. PubMed ID: 23918806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EZH2 dependent H3K27me3 is involved in epigenetic silencing of ID4 in prostate cancer.
    Chinaranagari S; Sharma P; Chaudhary J
    Oncotarget; 2014 Aug; 5(16):7172-82. PubMed ID: 25115397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. H2AK119Ub1 and H3K27Me3 in molecular staging for survival prediction of patients with pancreatic ductal adenocarcinoma.
    Chen S; Chen J; Zhan Q; Zhu Y; Chen H; Deng X; Hou Z; Shen B; Chen Y; Peng C
    Oncotarget; 2014 Nov; 5(21):10421-33. PubMed ID: 25431952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association between histone 3 lysine 27 trimethylation (H3K27me3) and prostate cancer: relationship with clinicopathological parameters.
    Ngollo M; Lebert A; Dagdemir A; Judes G; Karsli-Ceppioglu S; Daures M; Kemeny JL; Penault-Llorca F; Boiteux JP; Bignon YJ; Guy L; Bernard-Gallon D
    BMC Cancer; 2014 Dec; 14():994. PubMed ID: 25535400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone trimethylation of the p53 gene by expression of a constitutively active prolactin receptor in prostate cancer cells.
    Tan D; Tan S; Zhang J; Tang P; Huang J; Zhou W; Wu S
    Chin J Physiol; 2013 Oct; 56(5):282-90. PubMed ID: 24032713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EZH2-induced H3K27me3 is associated with epigenetic repression of the ARHI tumor-suppressor gene in ovarian cancer.
    Fu Y; Chen J; Pang B; Li C; Zhao J; Shen K
    Cell Biochem Biophys; 2015 Jan; 71(1):105-12. PubMed ID: 25077680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The EZH2- H3K27me3-DNMT1 complex orchestrates epigenetic silencing of the wwc1 gene, a Hippo/YAP pathway upstream effector, in breast cancer epithelial cells.
    Liu X; Li C; Zhang R; Xiao W; Niu X; Ye X; Li Z; Guo Y; Tan J; Li Y
    Cell Signal; 2018 Nov; 51():243-256. PubMed ID: 30121333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation.
    Zhou Z; Gao J; Popovic R; Wolniak K; Parimi V; Winter JN; Licht JD; Chen YH
    Leuk Lymphoma; 2015; 56(10):2895-901. PubMed ID: 25651430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p38-mediated phosphorylation at T367 induces EZH2 cytoplasmic localization to promote breast cancer metastasis.
    Anwar T; Arellano-Garcia C; Ropa J; Chen YC; Kim HS; Yoon E; Grigsby S; Basrur V; Nesvizhskii AI; Muntean A; Gonzalez ME; Kidwell KM; Nikolovska-Coleska Z; Kleer CG
    Nat Commun; 2018 Jul; 9(1):2801. PubMed ID: 30022044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EZH2 methyltransferase and H3K27 methylation in breast cancer.
    Yoo KH; Hennighausen L
    Int J Biol Sci; 2012; 8(1):59-65. PubMed ID: 22211105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PRC2-Mediated Epigenetic Suppression of Type I IFN-STAT2 Signaling Impairs Antitumor Immunity in Luminal Breast Cancer.
    Hong J; Lee JH; Zhang Z; Wu Y; Yang M; Liao Y; de la Rosa R; Scheirer J; Pechacek D; Zhang N; Xu Z; Curiel T; Tan X; Huang TH; Xu K
    Cancer Res; 2022 Dec; 82(24):4624-4640. PubMed ID: 36222718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.
    McCabe MT; Ott HM; Ganji G; Korenchuk S; Thompson C; Van Aller GS; Liu Y; Graves AP; Della Pietra A; Diaz E; LaFrance LV; Mellinger M; Duquenne C; Tian X; Kruger RG; McHugh CF; Brandt M; Miller WH; Dhanak D; Verma SK; Tummino PJ; Creasy CL
    Nature; 2012 Dec; 492(7427):108-12. PubMed ID: 23051747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.